Objective — to investigate the efficiency of monotherapy (local destruction of lesion foci) and combined treatment (the etiotropic drug Syperlymph and radiowave destruction) in patients with human papillomavirus infection and low-grade squamous cervical intraepithelial neoplasia. Subject and methods. A total of 160 women with high-risk human papillomaviruses detected by polymerase chain reaction were followed up. All the patients underwent a comprehensive examination including cytological and bacteriological examinations, polymerase chain reaction assay, determination of the gene expression profile of matrix RNA and the expression of the most informative markers of the inflammatory process in the scraping of the epithelium of the cervical canal, and extended colposcopy. After obtaining cytologic findings, a group of 60 patients with low-grade cervical intraepithelial neoplasia was made up and divided into 2 subgroups: a study group (n=36) that used combined treatment (Syperlymph and radio wave destruction) and a control group (n=24) who had only local monodestruction. Results. The use of Superlymph in the combination therapy contributed to a more rapid cervical cytological normalization after destructive treatment, to more effective human papillomavirus elimination and reduced local inflammation in comparison with these indicators in the control group. Conclusion. Superlymph has been shown to be effective in treating patients with low-grade cervical intraepithelial lesion associated with papillomavirus infection, which allows this drug to be recommended for widespread use in this pathology.